Green Shield Canada (GSC), a not-for-profit health benefits company that offers employee group health benefits that supplement government-sponsored provincial health plans, has announced a new program to switch patients to biosimilar therapies.
Green Shield Canada (GSC), a not-for-profit health benefits company that offers employee group health benefits that supplement government-sponsored provincial health plans, has announced a new program to switch patients to biosimilar therapies.
Beginning in 2016, GSC began to prefer available biosimilars and follow-ons (which it then referred to as “subsequent-entry biologics”) on its formulary, and required patients initiating treatment to use these preferred products. GSC’s next effort is to implement a “biosimilar transition program” in which patients already receiving originator biologics will switch to biosimilars.
“The evidence has rapidly accumulated over the last [2] years, and it is all pointing in the same direction: patients can safely transition from an originator biologic to a biosimilar product with no loss of clinical benefit and no compromise in safety,” said the payer in a statement.
The program will initially apply to a select group of plans for patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who are currently receiving branded etanercept (Enbrel) and infliximab (Remicade). As more biosimilars and more indications are approved, and as evidence on the feasibility of switching accumulates, the plan will increase the number of drugs and indications eligible for the transition program.
To help ensure a successful switch, the GSC says that it will use a “strong support system” that includes a dedicated team of care-coordinator nurses to help guide patients through the process, and news of the switch will be communicated to patients via a letter that outlines their options. First, patients may choose to undertake the switch after having discussed it with their provider. Second, they may choose to continue on their current treatment and pay the difference in costs between the biosimilar and the reference starting 60 days after the date of the letter. No claims for originator biologics will be denied; all claims will be paid based on the price of the biosimilar.
GSC has long been vocal in its calls for private payers in Canada to make greater use of biosimilars for the purpose of cost containment. In a statement in September 2017, the payer said that, though it has just 7% market share in Canada, due to its policy of beginning new starts on biosimilars, it generated 37% of claims for biosimilar infliximab (Inflectra) in the private market.
The payer has called on fellow companies to stop “signing up for the easy deals” in contracts with reference product sponsors to secure formulary placement. “We’re hoping to see more of our friends in the industry join us to support building a viable biosimilar market in Canada through forward-looking strategies. We did it for generics last decade, so we can do it again.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.